 The aim of this study is to demonstrate that OSE2101 Arm A is superior to standard chemotherapy, pemetrexed or docetaxel Arm B, in prolonging overall survival OS in HLA-A2 positive patients with locally advanced IIIB or metastatic IV NSCLC as 2nd or 3rd line therapy after failure of prior platinum-based chemotherapy or after failure of platinum- and checkpoint-inhibitor regimens. 